|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RHNO1 |
Gene summary for RHNO1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RHNO1 | Gene ID | 83695 |
| Gene name | RAD9-HUS1-RAD1 interacting nuclear orphan 1 | |
| Gene Alias | C12orf32 | |
| Cytomap | 12p13.33 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q9BSD3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 83695 | RHNO1 | LZE4T | Human | Esophagus | ESCC | 1.58e-03 | 1.49e-01 | 0.0811 |
| 83695 | RHNO1 | LZE7T | Human | Esophagus | ESCC | 1.42e-04 | 3.17e-01 | 0.0667 |
| 83695 | RHNO1 | LZE8T | Human | Esophagus | ESCC | 4.00e-10 | 3.81e-01 | 0.067 |
| 83695 | RHNO1 | LZE20T | Human | Esophagus | ESCC | 1.63e-04 | 1.74e-01 | 0.0662 |
| 83695 | RHNO1 | LZE22T | Human | Esophagus | ESCC | 1.01e-02 | 3.29e-01 | 0.068 |
| 83695 | RHNO1 | LZE24T | Human | Esophagus | ESCC | 8.46e-16 | 4.28e-01 | 0.0596 |
| 83695 | RHNO1 | LZE21T | Human | Esophagus | ESCC | 6.51e-03 | 2.20e-01 | 0.0655 |
| 83695 | RHNO1 | LZE6T | Human | Esophagus | ESCC | 1.96e-04 | 2.32e-01 | 0.0845 |
| 83695 | RHNO1 | P1T-E | Human | Esophagus | ESCC | 2.34e-02 | 2.62e-01 | 0.0875 |
| 83695 | RHNO1 | P2T-E | Human | Esophagus | ESCC | 3.04e-45 | 8.27e-01 | 0.1177 |
| 83695 | RHNO1 | P4T-E | Human | Esophagus | ESCC | 5.07e-46 | 1.05e+00 | 0.1323 |
| 83695 | RHNO1 | P5T-E | Human | Esophagus | ESCC | 1.76e-16 | 3.45e-01 | 0.1327 |
| 83695 | RHNO1 | P8T-E | Human | Esophagus | ESCC | 2.39e-23 | 4.36e-01 | 0.0889 |
| 83695 | RHNO1 | P9T-E | Human | Esophagus | ESCC | 3.97e-07 | 2.32e-01 | 0.1131 |
| 83695 | RHNO1 | P10T-E | Human | Esophagus | ESCC | 2.54e-17 | 4.33e-01 | 0.116 |
| 83695 | RHNO1 | P12T-E | Human | Esophagus | ESCC | 8.97e-42 | 8.21e-01 | 0.1122 |
| 83695 | RHNO1 | P15T-E | Human | Esophagus | ESCC | 5.33e-24 | 5.32e-01 | 0.1149 |
| 83695 | RHNO1 | P16T-E | Human | Esophagus | ESCC | 2.22e-13 | 3.36e-01 | 0.1153 |
| 83695 | RHNO1 | P17T-E | Human | Esophagus | ESCC | 8.33e-07 | 3.10e-01 | 0.1278 |
| 83695 | RHNO1 | P19T-E | Human | Esophagus | ESCC | 8.75e-05 | 4.85e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| GO:003464413 | Esophagus | ESCC | cellular response to UV | 70/8552 | 90/18723 | 4.59e-10 | 1.20e-08 | 70 |
| GO:007121419 | Esophagus | ESCC | cellular response to abiotic stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:010400419 | Esophagus | ESCC | cellular response to environmental stimulus | 206/8552 | 331/18723 | 7.52e-10 | 1.88e-08 | 206 |
| GO:004578710 | Esophagus | ESCC | positive regulation of cell cycle | 196/8552 | 313/18723 | 9.27e-10 | 2.24e-08 | 196 |
| GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
| GO:007147816 | Esophagus | ESCC | cellular response to radiation | 122/8552 | 186/18723 | 3.07e-08 | 5.73e-07 | 122 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:0071479110 | Esophagus | ESCC | cellular response to ionizing radiation | 54/8552 | 72/18723 | 3.85e-07 | 5.32e-06 | 54 |
| GO:00315705 | Esophagus | ESCC | DNA integrity checkpoint | 83/8552 | 123/18723 | 8.17e-07 | 1.06e-05 | 83 |
| GO:00000775 | Esophagus | ESCC | DNA damage checkpoint | 78/8552 | 115/18723 | 1.27e-06 | 1.56e-05 | 78 |
| GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
| GO:00900689 | Esophagus | ESCC | positive regulation of cell cycle process | 142/8552 | 236/18723 | 4.79e-06 | 5.08e-05 | 142 |
| GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
| GO:00714821 | Esophagus | ESCC | cellular response to light stimulus | 75/8552 | 123/18723 | 4.45e-04 | 2.50e-03 | 75 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RHNO1 | SNV | Missense_Mutation | c.27N>T | p.Gln9His | p.Q9H | Q9BSD3 | protein_coding | tolerated(0.67) | benign(0.01) | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RHNO1 | SNV | Missense_Mutation | novel | c.541N>C | p.Ser181Arg | p.S181R | Q9BSD3 | protein_coding | tolerated(0.36) | benign(0.022) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RHNO1 | SNV | Missense_Mutation | novel | c.236N>G | p.Ala79Gly | p.A79G | Q9BSD3 | protein_coding | deleterious(0.04) | possibly_damaging(0.82) | TCGA-B6-A0I2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RHNO1 | SNV | Missense_Mutation | c.631N>C | p.Val211Leu | p.V211L | Q9BSD3 | protein_coding | deleterious(0) | possibly_damaging(0.687) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RHNO1 | SNV | Missense_Mutation | c.647N>A | p.Arg216Gln | p.R216Q | Q9BSD3 | protein_coding | deleterious(0.02) | possibly_damaging(0.472) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RHNO1 | SNV | Missense_Mutation | novel | c.16N>C | p.Lys6Gln | p.K6Q | Q9BSD3 | protein_coding | deleterious(0.01) | possibly_damaging(0.758) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| RHNO1 | SNV | Missense_Mutation | novel | c.400C>T | p.Pro134Ser | p.P134S | Q9BSD3 | protein_coding | deleterious(0.04) | possibly_damaging(0.871) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RHNO1 | SNV | Missense_Mutation | novel | c.542N>A | p.Ser181Asn | p.S181N | Q9BSD3 | protein_coding | tolerated(0.29) | possibly_damaging(0.571) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RHNO1 | SNV | Missense_Mutation | novel | c.502G>A | p.Glu168Lys | p.E168K | Q9BSD3 | protein_coding | tolerated(0.83) | benign(0.001) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RHNO1 | SNV | Missense_Mutation | c.62N>T | p.Gln21Leu | p.Q21L | Q9BSD3 | protein_coding | tolerated(0.16) | benign(0.215) | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |